Jason Visit 1: A young man with schizophrenia recently discharged from hospital

Virtual Clinic Powered by RealCME with content provided by its educational partners

Title:	Jason Visit 1: A young man with schizophrenia recently discharged from hospital
Topic:	Psychiatry
Relevant Terms:	Psychosis, Schizophrenia
Primary Audience:	Psychiatrists
Launch Date:	08-Oct-10
Credits:	0.75 AMA PRA Category 1 Credit™
Expiration Date:	The accreditation for this activity has expired.
Curriculum Name:	Overcoming Obstacles to Remission and Recovery in Patients With Schizophrenia

Enter this activity!

Learning Objectives

Upon completion of the activity, participants should be able to:

Individualize treatment plans for patients with schizophrenia to achieve patient‑directed goals for functional outcomes
Apply evidence-based management strategies with a recovery-oriented perspective in patients with schizophrenia
Establish a physician–patient collaboration by fostering a sense of shared decision making
Create relapse prevention plans for patients with schizophrenia
Improve clinical outcomes by recognizing the potential for cognitive dysfunction, negative symptoms, and poor physical health—and addressing these issues—in patients with schizophrenia

Faculty

Alex J. Kopelowicz, MD
Professor and Vice-Chair
Department of Psychiatry & Biobehavioral Sciences
David Geffen School of Medicine at UCLA
Los Angeles, California

Peter J. Weiden, MD
Director, Psychotic Disorders Program
Center for Cognitive Medicine
Professor, Department of Psychiatry
University of Illinois at Chicago
Chicago, Illinois

Robert P. Liberman, MD
Distinguished Professor of Psychiatry
UCLA Department of Psychiatry & Biobehavioral Sciences
Director, UCLA Psych REHAB Program
Semel Institute of Neuroscience & Human Behavior
Los Angeles, California

Robert P. Liberman, MD

Robert P. Liberman, MD, is Distinguished Professor of Psychiatry in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine of the University of California at Los Angeles, where he directs the Psychiatric Rehabilitation Program. Dr. Liberman received his medical degree from Dartmouth Medical School. He completed his internship at the Albert Einstein College of Medicine in New York City and his residency in psychiatry at the Massachusetts Mental Health Center in Boston. He subsequently held a fellowship from Harvard Medical School.

Dr. Liberman has put rehabilitation of the seriously mentally ill on the psychiatric map. Since the 1960s, he has developed, empirically validated, and disseminated evidence-based treatments that have enabled persons with schizophrenia and other mental disabilities to recover and reintegrate into community life. He and his colleagues were the first to use social skills training, behavioral family therapy, and cognitive remediation and to document their effectiveness in the treatment of schizophrenia. To overcome barriers to widespread adoption of psychosocial rehabilitation, Dr. Liberman's team of scientist-practitioners created a series of nine video-assisted modules, or curricula, for teaching social and independent living skills to the seriously mentally ill. The modules, such as Symptom Self-Management, Medication Self-Management, Community Re-Entry, Workplace Fundamentals, Basic Conversation Skills, and Friendship & Intimacy, have been translated into 23 languages and used throughout the world.

The recipient of many national and international honors and awards, a Distinguished Life Fellow of the American Psychiatric Association, and a present or past member of a number of editorial boards of peer-reviewed journals across the world, Dr. Liberman is widely published. His latest book, Recovery from Disability, is a practical guide for clinicians who wish to engage their mentally ill patients on a journey to recovery. He has authored or coauthored many articles, which have appeared in such peer-reviewed journals as Psychiatric Services, the Journal of Mental Health, and The American Journal of Psychiatry.

Course Viewing Requirements

PC
Internet Explorer (v6 or greater), or Firefox

MAC
Safari

Estimated time to complete activity: 0.75 hours

Sponsored by

Supported by an educational grant from

Target Audience

This activity has been designed to meet the educational needs of psychiatrists and other mental health care providers involved in the management of patients with schizophrenia.

Program Overview

Treatment of schizophrenia by psychiatrists is commonly limited to interventions that mitigate the patient's positive symptoms, which are the most immediate and often considered the most debilitating. In contrast, management of global patient health, including negative symptoms, cognitive function, and physical health that may be impaired due to adverse events from medications, is underemphasized in clinical care. Yet, these aspects are essential to remission, longer-term recovery, and improved societal functioning—the eventual goals of treatment.

This activity will focus on helping psychiatrists to set patient-directed goals and make evidence-based management decisions aimed at assisting their patients toward progress in recovery.

Accreditation Statement

SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

SciMed designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure and Resolution of Conflicts of Interest

SciMed requires all individuals who are involved with the development or delivery of content in any of its activities to disclose financial relationships they may have with commercial interests. Should SciMed determine that any of the disclosed relationships constitutes a conflict of interest, as defined by the ACCME, SciMed will act to resolve such a conflict.

When asked to report relevant financial relationships with commercial interests, faculty reported the following:

Alex J. Kopelowicz, MD

No relevant financial relationships to report

Robert P. Liberman, MD

Consultant: Psychiatric Rehabilitation Consultants

Peter J. Weiden, MD (past 3 years)

Grants/Research Support: AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceutica, Otsuka America Pharmaceuticals, Pfizer, Inc.

Speakers Bureau: AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceutica, Pfizer, Inc.

Consultant: AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceutica, Organon USA, Otsuka America Pharmaceuticals, Pfizer, Inc. (self and spouse), Shire, Vanda Pharmaceuticals, Wyeth

Shari Fallet, DO, an employee of SciMed and a member of the planning committee for this activity, reports owning stock in Pfizer, Inc. All other SciMed personnel involved in the development of content for this activity have no relevant financial relationships to report.

The materials for this activity were peer reviewed by Jeffrey R. Strawn, MD, Assistant Professor, Departments of Psychiatry and Behavioral Neuroscience and Pediatrics, University of Cincinnati College of Medicine. Dr. Strawn has no relevant financial relationships to report.

Off-label Product Discussion
Faculty have indicated that this activity will include off-label information on dosing of approved antipsychotic medications for schizophrenia.

Instructions for Participating in This Activity and Obtaining CME Credit

There are no fees for participating in and receiving CME credit for this online educational activity. To obtain CME credit for participating in this activity during the period October 8, 2010 through October 8, 2011, participants must 1) read the educational objectives and disclosure statements; 2) study the educational activity; and 3) participate in the postactivity exercise. Once you have completed the educational activity and postactivity exercise, you will be directed to complete an evaluation form.

Disclaimer

The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of SciMed or the commercial supporter(s). Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.

Enter this activity!

These activities require registration. Registration time is less than two minutes, and will provide you access to your personal CMECompanion toolset.

If you are already registered, please log in.

(+) What is CMECompanion?